Technical Analysis for IVA - Inventiva S.A.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.47 | -3.31% | -0.12 |
IVA closed down 3.31 percent on Friday, May 24, 2024, on 16 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: May 29
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 50 DMA Support | Bullish | -3.31% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.31% | |
| 50 DMA Support | Bullish | -6.85% | |
| Overbought Stochastic | Strength | -6.85% | |
| Gapped Down | Weakness | -6.85% | |
| Narrow Range Bar | Range Contraction | -9.06% |
| Alert | Time |
|---|---|
| 50 DMA Support | 3 days ago |
| 20 DMA Resistance | 4 days ago |
| 20 DMA Support | 4 days ago |
| Gapped Down (Full) | 4 days ago |
| Down 3% | 4 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/29/2024
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Alcohol Genetics Gene Expression Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease DNA Fibrosis Small Molecule Therapies Transcription Transcription Factors Epigenetics Transcription Factor Hepatitis A
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Alcohol Genetics Gene Expression Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease DNA Fibrosis Small Molecule Therapies Transcription Transcription Factors Epigenetics Transcription Factor Hepatitis A
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.04 |
| 52 Week Low | 2.93 |
| Average Volume | 34,454 |
| 200-Day Moving Average | 3.85 |
| 50-Day Moving Average | 3.57 |
| 20-Day Moving Average | 3.49 |
| 10-Day Moving Average | 3.67 |
| Average True Range | 0.19 |
| RSI (14) | 46.81 |
| ADX | 22.02 |
| +DI | 25.59 |
| -DI | 22.06 |
| Chandelier Exit (Long, 3 ATRs) | 3.34 |
| Chandelier Exit (Short, 3 ATRs) | 3.62 |
| Upper Bollinger Bands | 3.91 |
| Lower Bollinger Band | 3.08 |
| Percent B (%b) | 0.47 |
| BandWidth | 23.85 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.0128 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.70 | ||||
| Resistance 3 (R3) | 3.72 | 3.65 | 3.66 | ||
| Resistance 2 (R2) | 3.65 | 3.59 | 3.64 | 3.65 | |
| Resistance 1 (R1) | 3.56 | 3.55 | 3.60 | 3.54 | 3.64 |
| Pivot Point | 3.49 | 3.49 | 3.51 | 3.48 | 3.49 |
| Support 1 (S1) | 3.40 | 3.43 | 3.44 | 3.39 | 3.29 |
| Support 2 (S2) | 3.33 | 3.39 | 3.32 | 3.28 | |
| Support 3 (S3) | 3.24 | 3.33 | 3.27 | ||
| Support 4 (S4) | 3.23 |
